Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia (Q37059746)

From Wikidata

Jump to navigation Jump to search

scientific article published on January 2008

Language	Label	Description	Also known as
English	Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia	scientific article published on January 2008

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

4 references

13 March 2019

3 April 2019

4 August 2019

28 September 2019

Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia (English)

1 reference

Europe PubMed Central

18 August 2017

chronic myeloid leukemia

4 references

13 March 2019

3 April 2019

4 August 2019

28 September 2019

precursor lymphoblastic lymphoma/leukemia

4 references

13 March 2019

3 April 2019

4 August 2019

28 September 2019

Src family kinase

1 reference

4 August 2019

1 reference

28 September 2019

1 reference

based on heuristic

inferred from title

author name string

Shaoguang Li

1

1 reference

Europe PubMed Central

18 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2008

5 references

Europe PubMed Central

18 August 2017

13 March 2019

3 April 2019

4 August 2019

28 September 2019

Leukemia & Lymphoma

5 references

Europe PubMed Central

18 August 2017

13 March 2019

3 April 2019

4 August 2019

28 September 2019

49

1 reference

Europe PubMed Central

18 August 2017

1

1 reference

Europe PubMed Central

18 August 2017

19-26

1 reference

Europe PubMed Central

18 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

4 references

Europe PubMed Central

13 March 2019

Europe PubMed Central

3 April 2019

Europe PubMed Central

4 August 2019

Europe PubMed Central

28 September 2019

copyright status

0 references

on focus list of Wikimedia project

0 references

Important therapeutic targets in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Src kinases as targets for B cell acute lymphoblastic leukaemia therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Structure and regulation of Src family kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Clinical resistance to imatinib: mechanisms and implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Two distinct phosphorylation pathways have additive effects on Abl family kinase activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Src family tyrosine kinases and growth factor signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

The molecular genetics of Philadelphia chromosome-positive leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

29 September 2017

Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Acute leukaemia in bcr/abl transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

27 June 2018

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

BCR-ABL down-regulates the DNA repair protein DNA-PKcs

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

The neuropathologic phenotype of experimental ovine BSE is maintained after blood transfusion.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

4 September 2018

Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430171

4 September 2018

Expression of v-src induces a myeloproliferative disease in bone-marrow-reconstituted mice

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Circumventing Resistance to Kinase-Inhibitor Therapy

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1080%2F10428190701713689

21 January 2018

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow

1 reference

https://pubmed.ncbi.nlm.nih.gov/18203007

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1080/10428190701713689

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37059746&oldid=2157028835"